Benefits
Digestive comfort: no significant difference versus placebo
In the one trial cited here, diarrhea-related scores improved from the starting point within the BB536 group, but there was no significant difference versus placebo across the full group of 60 athletes. Constipation and regularity were not outcomes of that trial, so nothing on this page supports a claim about them.
What the athlete trial did not measure
The 4 week athlete trial cited on this page took no immune measurements, so it says nothing either way about immune defenses. The separate respiratory illness and influenza trials of BB536 are summarized in the upper respiratory benefit below.
Gut bacteria measures: no change found
In the cited 4 week trial, gut microbiota measures and metabolite profiles did not differ significantly between BB536 and placebo for the group as a whole. Differences turned up only in small subgroups defined by each person's starting bacteria, which the authors treat as early ideas to test later, not as proof.
Upper respiratory immune support, studied in children and older adults
Two trials of BB536 itself. 520 preschoolers took 5 billion CFU daily or placebo for 10 months; only the 219 fully compliant were analyzed, with fewer respiratory illnesses and 46% shorter sore throats, but no clear fever or cough effect. 27 elderly adults took 100 billion CFU daily for 5 weeks, then were randomized to it or placebo for 14 weeks; fewer on BB536 had influenza or fever. Both are maker-coauthored; the elderly one is tiny.
Mechanism of action
Bifidobacterial colonization
The proposed idea is that BB536 passes through the gut, competes with less desirable microbes, and shifts the metabolites bacteria produce. In the trial cited here, both microbiota measures and metabolite profiles were no different from placebo, so this stays a theory rather than something the page's evidence shows.
Immune modulation (theory only, not measured here)
Gut bacteria interact with immune tissue in the gut wall, which is the general reason probiotics get studied for immune effects. That is background biology. The athlete trial cited here measured no immune outcome, but in a 4 week placebo-controlled trial in 97 healthy adults, 10 billion CFU a day of BB536 raised an activation marker (CD86) on plasmacytoid dendritic cells, a type of immune cell. That is a lab marker, not an illness outcome.
Clinical trials
Exploratory randomized, double-blind, placebo-controlled trial. 46 billion CFU per day of BB536 for 4 weeks, with both groups also taking 70 g per day of whey protein. (Miyamoto et al. 2026, Journal of the International Society of Sports Nutrition)
60 healthy male athletes, average age about 18.6 years, all on a high protein diet.
In the overall group there were no significant differences between BB536 and placebo in gastrointestinal outcomes, gut microbiota measures, or metabolite profiles. Diarrhea scores improved from baseline within the BB536 group, and some differences showed up in subgroups defined by starting gut bacteria, but the authors state these should be read as exploratory and hypothesis-generating because they did not extend to the full group. The study also cannot separate BB536 from the whey protein everyone was taking.